NEW YORK (GenomeWeb) – Transgenomic and privately held Precipio Diagnostics said today that they have entered into a merger agreement that will make Precipio a wholly owned subsidiary of Transgenomic, with Transgenomic adopting the name Precipio, Inc.
The merger, expected to close in 2016, is pending approval by Transgenomic shareholders.